Rep. DeLauro seeks FDA rule on BPA product disclosure
This article was originally published in The Gray Sheet
Executive Summary
Rep. Rosa DeLauro, D-Conn., seeks expansion of the FDA Science Board's inquiry into the toxicity and risks of bisphenol A (BPA) to include use of the chemical in medical devices, and requests a list of all medical devices that contain the chemical, in a June 16 letter to FDA Chief Scientist Frank Torti. The agency contends that the board already plans to review all FDA regulated products containing BPA, including medical devices, and that an agency-wide BPA task force formed in April is assembling an inventory of FDA-regulated products that contain BPA. The congresswoman believes FDA should require device makers to identify which of their products include BPA, after Canada's issuance of a similar rule last month. A subcommittee of the Science Board is planning an upcoming meeting on the safety of BPA in plastics ("1The Gray Sheet" May 12, 2008, p. 6)
You may also be interested in...
FDA Task Force Takes Hard Look At Leachable Chemical In Medical Products
FDA is stepping up research into a chemical used in some plastics, including medical devices, in the wake of a recent National Institutes of Health brief outlining related safety concerns
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.